home / stock / iphyf / iphyf quote
Last: | $1.9301 |
---|---|
Change Percent: | 0.0% |
Open: | $1.9301 |
Close: | $1.9301 |
High: | $1.9301 |
Low: | $1.9301 |
Volume: | 500 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.9301 | $1.9301 | $1.9301 | $1.9301 | $1.9301 | 500 | 07-05-2024 |
$2.49 | $2.49 | $2.49 | $2.49 | $2.49 | 500 | 06-13-2024 |
$2.67 | $2.67 | $2.67 | $2.67 | $2.67 | 5,000 | 06-07-2024 |
$2.77 | $2.77 | $2.77 | $2.77 | $2.77 | 200 | 06-05-2024 |
$2.2 | $0 | $2.2 | $0 | $0 | 35 | 05-23-2024 |
$2.2 | $0 | $2.2 | $0 | $0 | 1 | 05-20-2024 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 100 | 05-08-2024 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 10,000 | 05-07-2024 |
$2.13 | $2.13 | $2.13 | $2.13 | $2.13 | 2,000 | 05-03-2024 |
$2.65 | $2.43 | $2.65 | $2.65 | $2.43 | 300 | 04-02-2024 |
$2.58 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 03-29-2024 |
$2.58 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 03-28-2024 |
$2.3405 | $2.3405 | $2.3405 | $2.3405 | $2.3405 | 200 | 03-27-2024 |
$2.395 | $2.395 | $2.395 | $2.395 | $2.395 | 100 | 03-19-2024 |
$2.44 | $2.44 | $2.44 | $2.44 | $2.44 | 100 | 03-11-2024 |
$2.52 | $2.52 | $2.52 | $2.52 | $2.52 | 200 | 03-06-2024 |
$2.84 | $0 | $2.84 | $0 | $0 | 5 | 01-05-2024 |
$2.84 | $2.895 | $2.84 | $2.895 | $2.84 | 300 | 01-01-2024 |
$2.84 | $2.895 | $2.84 | $2.895 | $2.84 | 300 | 12-29-2023 |
$2.65 | $2.65 | $2.65 | $2.65 | $2.65 | 200 | 12-27-2023 |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...